Oventus: Treat Sleep Apnea with 3D Titanium Printing

When
JANUARY 21ST, 2017
FROM: 10:30AM TO 1PM

Where
PIVOTAL, 5TH FLOOR 875 HOWARD STREET
SAN FRANCISCO, CA, USA

https://events.bizzabo.com/OVENTUS

A New Paradigm for Treating Obstructive Sleep Apnea

Do your patients have obstructive sleep apnea? Is CPAP the best choice? Now, there is a smaller and more comfortable device which allows for higher patient satisfaction and is often as effective as CPAP for patients with mild to moderate sleep apnea.

The Oventus O2Vent is the world’s first and only 3D titanium printed device with a unique airway design that allows air to flow through to the back of the throat bypassing obstructions within the nasal passage and collapse of the tongue and soft palate. More information can be found using this link http://www.ussleepapnea.com/3d-printing.html. This patented airway design will enable future product developments for CPAP connection and compliance monitoring. Come and learn more about the Oventus O2Vent, which will be an effective alternative treatment for many of your patients suffering from obstructive sleep apnea. Oventus is celebrating their launch in the USA in accordance with Australian Innovation Week and the successful collaboration with the Commonwealth Science and Industrial Research Organisation (CSIRO) that made this innovative 3D printed titanium design possible.

https://events.bizzabo.com/OVENTUS

Our Speakers

speaker image
Craig Laundy
Assistant Minister of Industry, Innovation and Science
House of Representatives, Parliament of Australia

speaker image
Lindsay Adler
Executive Manager, Global, CSIRO
Commonwealth Scientific and Industrial Research Organisation (CSIRO)

speaker image
Elise Hogan
Vice President of Global Sales, Marketing and Commercialisation
Oventus Pty Ltd

speaker image
Dr. Amanda Cheng
Co-Founder/ CEO
US Sleep Apnea

speaker image
Dr. Michael Sodeifi
Co-Founder/ Clinical Director
US Sleep Apnea

speaker image
Jenny Chen
Founder/CEO
3DHeals

Agenda

  • The Oventus story: Elise Hogan
  • Opening Message: Craig Laundy ( Assistant Minister of Industry, Innovation, and Science) and Commonwealth Science and Industrial ResearchOrganisation (CSIRO)  Driving Innovation Through Research
  • Partners in Innovation: Mr. Lindsay Alder, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Executive Manager, Global Operations
  • Clinical Insights with Sleep Apnea Specialists: Dr. Amanda Cheng and Dr.Michael Sodeifi
  • 3D Printing in Healthcare Innovation: Dr. Jenny Chen (3DHEALS)

https://events.bizzabo.com/OVENTUS

registernow

 

New sleep apnea device hits U.S. market

BRISBANE, Australia – Oventus on Jan. 16 announced the U.S. launch of O2Vent, what it calls the first and only sleep disorder device cleared by the Food and Drug Administration that provides relief for snoring and obstructive sleep apnea via a unique, separate airway that avoids multiple sites of obstruction, including the nose, soft palate and the tongue. The device, which uses 3D printing technologies and is customized for each patient from medical-grade titanium, works by stabilizing the jaw position, bringing the tongue forward to reduce airway collapse, according to a press release. Oventus is launching the device first in San Francisco, as part of the G’Day Australia events being held there on Jan. 21.

Oventus Announces O2Vent T Device for Sleep Apnea

Approximately 12 to 18 million American adults suffer from sleep apnea, according to the National Heart, Lung, and Blood Institute.

To provide relief, Oventus, a medical device company from Brisbane, Australia, developed the O2Vent T, a medical device that provides relief for snoring and obstructive sleep apnea (OSA).

Using 3D printing technology, the O2Vent T stabilizes the jaw position by bringing the tongue forward to reduce airway collapse. It is designed with medical-grade titanium, customized for each patient, and a “duckbill” (whistle) design that creates the seperate airway to the back of the mouth.

“O2Vent T is unique because the patented airway design allows patients to breathe through a separate airway, which has never been done before,” according to Dr. Chris Hart, Founder and Clinical Director for Oventus. “This differentiated design essentially acts as a second ‘nose’ for patients and may be a more comfortable solution than other technologies on the market for the millions of patients who suffer from untreated OSA.”

Hart was inspired to create the first O2Vent T prototype, the O2Vent Mono, due to personal history with sleep apnea.

OSA is caused by an obstruction in the throat that restricts air flow, causing people to stop breathing. OSA can lead to high blood pressure, stroke, irregular heartbeats, and diabetes, according to Oventus. Those who are overweight or are obese are at a higher risk for OSA.

Check out this video – https://www.youtube.com/watch?v=QiV5LXlbEFA

“The rising epidemic of OSA and its consequences are under-diagnosed and marginally managed at best,” states Dr. Michael Sodeifi, an oral and maxillofacial surgeon and one of the first clinicians in San Francisco to treat patients with O2Vent T. “It has huge impacts on society by adversely affecting our physical and mental health, personal relationships and job performance. As both a surgeon trained to treat this condition and a sufferer, I am very excited to be working with Oventus to introduce this device to other patients in the United States.”

This device will be launching in San Francisco on Jan. 21 during the G’Day Australia events. Other launch locations include San Francisco, Los Angeles, Boston, Leawood, KS and Delaware.

Courtesy – https://www.mdtmag.com/news/2017/01/oventus-announces-o2vent-t-device-sleep-apnea

Oventus announces U.S. launch of O2Vent T device for sleep apnea

Oventus, a Brisbane-based medical device company seeking to change the way sleep disorders are oventustreated, announced the U.S. launch of O2Vent T, the first and only FDA-cleared sleep disorder device that provides relief for snoring and obstructive sleep apnea (OSA) via a unique, separate airway that avoids multiple sites of obstruction, including the nose, the soft palate and the tongue. There is an estimated 50-70 million American adults that suffer from sleep disorders and 12-18 million adults that have sleep apnea.

The O2Vent T uses 3D printing technologies and is customized for each patient from medical-grade titanium, making it lighter and easier to wear than other devices intended to treat sleep disorders. The launch of O2Vent T is taking place in San Francisco during the G’Day Australia events being held Jan. 21. San Francisco will be the first market in the U.S. to offer this new technology to consumers.

A collaboration with Australia’s peak scientific body, the Commonwealth Scientific and Industrial Research Organization (CSIRO), has seen Oventus take its revolutionary technology global, offering real hope to millions of U.S. sufferers of OSA.  

“O2Vent T is unique because the patented airway design allows patients to breathe through a separate airway, which has never been done before,” said Dr. Chris Hart, founder and clinical director for Oventus. “This differentiated design essentially acts as a second ‘nose’ for patients and may be a more comfortable solution than other technologies on the market for the millions of patients who suffer from untreated OSA.”

The O2Vent T works by stabilizing the jaw position, bringing the tongue forward to reduce airway collapse. It is 3D printed in titanium and individually made to suit each individual user.  The O2Vent T was born out of Hart’s own personal experience and desperation for a good night’s sleep.  A self proclaimed “chainsaw snorer” and sleep apneic who also suffered nasal congestion, he fashioned the original prototype of what would become the O2Vent Mono. This novel invention is expanding into multiple global markets as the incidence of OSA and its associated myriad of health problems continues to grow.

OSA occurs when the air passage in the throat becomes obstructed during sleep and causes people to stop breathing. It is estimated that OSA affects approximately 12-18 million people in the U.S. This condition can have serious medical implications, including high blood pressure, stroke, irregular heartbeats and diabetes. Similarly, individuals who suffer from OSA often have other serious side effects which can impact personal relationships, work performance and overall quality of life, including: chronic fatigue or excessive daytime sleepiness, poor concentration, irritability and mood changes, impotence or sex drive changes. The majority of individuals who have OSA are overweight or obese. Other contributing factors include: alcohol consumption (particularly in the evening, before bed), certain thyroid illnesses, sedatives, nasal congestion and/or obstruction or facial bone shape and size of the muscles in the face or neck.

“The rising epidemic of OSA and its consequences are under-diagnosed and marginally managed at best,” said Dr. Michael Sodeifi, an oral and maxillofacial surgeon and one of the first clinicians in San Francisco to treat patients with O2Vent T. “It has huge impacts on society by adversely affecting our physical and mental health, personal relationships and job performance.  As both a surgeon trained to treat this condition and a sufferer, I am very excited to be working with Oventus to introduce this device to other patients in the United States.”

A 2016 clinical study showed Oventus’ first generation product, the O2Vent Mono, either eliminated or significantly reduced snoring in 100% of patients. A second clinical trial is currently under way to add to the growing body of evidence as the device is rolled out worldwide.

The O2Vent launch will initially roll out in in several markets in the U.S., including: San Francisco, Los Angeles, Boston, Leawood, Kan. and Delaware.

Oventus
oventus.com.au

Oventus opens Australian 3D printing facility for O2Vent sleep apnea device

 

 

Australian company Oventus Medical Ltd., known for its innovative 3D printed sleep apnea device, has seen quite a lot of success over the past year. Not only did it announce an expansion into the highly sought after U.S. market, but its shares also rose, and it raised $12 million in investments through a very successful IPO. Now, it seems its growth and good fortune are still going strong, as the company has just announced the launch of its new Victorian 3D printing facility today.

oventus-launches-australian-3d-printing-facility-o2vent-sleep-apnea-device-1The additive manufacturing facility, which is located at CSIRO’s Clayton Site in Clayton, Australia, will be used to manufacture Oventus’ revolutionary O2Vent sleep apnea device. The device, which was developed to help sufferers of a relatively common condition known as sleep apnea (over 12 million in the U.S. alone are affected by it), will be made using state-of-the-art titanium 3D printing equipment.

According to the company, the launch of the new 3D printing facility marks a step forwards for Oventus’ collaboration with CSIRO (the Commonwealth Scientific and Industrial Research Organization). CSIRO, which has been a part of many 3D printing advancements and innovations within Australia, is certainly proving to be a fruitful example of what can be achieved when industry and researchers team up.

As Dr. Keith McLean, director of CSIRO Manufacturing, explained, “Combining our research team’s additive manufacturing experience with the software capabilities of CSIRO’s Data61, meant we could create a one stop in-house process for making personalized mouth pieces that are individualized for each Oventus customer. Additionally, we have been able to help Oventus upscale their manufacturing process to allow large volume manufacturing of the devices at the Clayton facility.”

The O2Vent is essentially a 3D printed titanium mouth guard that has been specially designed to help those suffering from sleep apnea, a sleep disorder which causes shallow breathing or even pauses in breathing during sleep. The 3D printed device helps to bypass the condition by opening up an airway and directing air flow to the back of the throat, circumventing the nose, soft palate, and tongue, which can be obtrusive to breathing.

As Oventus founder Dr. Chris Hart has explained, much of his company’s success was realized through the support of CSIRO’s research and state-of-the-art additive manufacturing technologies. “CSIRO were able to help us not only develop the 3D printing process, but also create the crucial software needed to design the individual devices. Because a patient’s bite is as individual as his fingerprint, we needed special software to help us create a perfectly customized O2Vent from a patient’s dental imprints.”

There is no doubt that with its new 3D printing facility at CSIRO, Oventus will be able to grow its business and continually develop its innovative product. Oventus is set to launch in the U.S. in 2017.

Article – https://filacart.com/blog/oventus-opens-australian-3d-printing-facility-for-o2vent-sleep-apnea-device/